Cost effectiveness sensitivity

This page is a encyclopedia article. The page identifier is Op_en6838
Moderator:Nobody (see all) Click here to sign up.
Upload data {{#opasnet_base_link:Op_en6838}}

The effects of alternative vaccine compositions on the outcomes of the cost-benefit analysis were assessed. Five modifications for PCV10 and one for PCV13 were considered

Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important.

 PCV13adv.inIPD 
   = (IPD under PCv10) - (IPD under PCV13)
   if positive, PCV13 saves IPD compared to PCV10

 price of PCV13 
   =  if PCV10 price set at 20e, what is the matching price for PCV13?

 ICER 
   = incremental cost-effectiveness ratio for PCV10 at price 20e
    (in this table, this value is also average cost per QALY)

 rows:
 [1]  pcv10       
 [2]  pcv10 + 19A(direct effects only)
 [3]  pcv10 + 6A      
 [4]  pcv10 + 19A(direct only) + 6A
 [5]  pcv10 + 19A(full)  
 [6]  pcv10 + 19A(full) + 6A = PCV13 - 3

 columns:
 [1]  pcv13 - 3 (excluding serotype 3)     
 [2]  pcv13

                 PCV13adv.inIPD   price of PCV13    ICER
                 ==============   ==============    ===============
                 PCV13-3  PCV13   PCV13-3  PCV13    PCV13-3   PCV13
                   ---     ---    -------  -----     -----     ----
  pcv10             12     150       18     38        8077     8077
  pcv10+19Ad        -2     134       17     37        7714     7714
  pcv10+6A          50     188       25     55       13590    13590
  pcv10+19Ad+6A     32     169       24     52       12724    12724
  pcv10+19Af       -31     105       15     32        6198     6199
  pcv10+19Af+6A      *     137        *     43           *     9672
                                 ----------------
                                 (PCV10 price=20)